Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Dr. Reddy’s: Consolidation woes - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Aug 5, 2003

    Dr. Reddy’s: Consolidation woes

    Domestic pharma major, Dr. Reddy's Laboratories (DRL) has recorded healthy growth in 1QFY04. While the topline increased by 30%, the bottomline grew by a strong 54%. However, on a consolidated basis, DRL has reported a meager 7% increase in total revenues and a 34% dip in net profits.

    Consolidated results
    (Rs m) 1QFY03 1QFY04 % change
    Net Sales 4,385 4,696 7.1%
    Other Income 131 222 69.8%
    Expenditure 2,841 3,586 26.2%
    Operating Profit (EBDIT) 1,544 1,109 -28.1%
    Operating Profit Margin (%) 35.2% 23.6%  
    Interest 15 4 -76.3%
    Depreciation 172 231 34.1%
    Profit before Tax 1,487 1,096 -26.3%
    Extraordinary income - -  
    Tax 168 219 30.1%
    Profit before Minority interest 1,318 877 -33.5%
    Minority interest 11 -  
    Profit after Tax (Consolidated) 1,329 877 -34.0%
    Net profit margin (%) 30.3% 18.7%
    No. of Shares (eoy) (m) 76.5 76.5  
    Fully Diluted Earnings per share* 69.5 45.9  
    P/E Ratio   22.6  
    * annualised      

    Although DRL has improved its operating efficiency on account of a better product mix, sharp increase in the selling, general and administrative (SGA) expenses as well as in the R&D expenditure has off-set this improvement, resulting in the company recording a drop in the operating margins. R&D expenditure, which stood at 6.8% of the total revenues, has increased primarily due to an increase in the number of bio-studies in generics and higher development activity in APIs. The increase in SGA expenses, on the other hand, was on account of an increase in the legal & consultancy charges and marketing expenses. However, a sharp drop in the interest expenses coupled with an increase in the other income (due to higher fixed deposit interest income) has helped the company register a sharp rise in the bottomline on a standalone basis.

    (Rs m) 1QFY03 1QFY04 % change
    Net Sales 3,350 4,343 29.6%
    Other Income 166 194 16.8%
    Expenditure 2,412 2,919 21.0%
    Operating Profit (EBDIT) 938 1,424 51.8%
    Operating Profit Margin (%) 28.0% 32.8%  
    Interest 14 3 -80.4%
    Depreciation 137 164 20.1%
    Profit before Tax 954 1,452 52.2%
    Extraordinary income - -  
    Tax 153 217 41.9%
    Profit after Tax/(Loss) 801 1,235 54.1%
    Net profit margin (%) 23.9% 28.4%
    No. of Shares (eoy) (m) 76.5 76.5  
    Fully Diluted Earnings per share* 41.9 64.6  
    P/E Ratio   16.1  
    * annualised      

    Let us take a detailed look at the consolidated revenue break-up for the company during the quarter.

    Revenue mix by geography
    (Rs m) 1QFY03 1QFY04 % change
    India 1,661 1,749 5.3%
    North America 1,657 1,554 -6.2%
    Russia 343 435 26.8%
    Europe 322 412 28.0%
    Others 550 662 20.4%
    Total 4,533 4,812 6.2%

    On observing the geographical revenue mix we see that although the North American markets have seen negative growth, strong performance in the Russian and European markets has helped the company. The growth in the European markets was fuelled by a strong performance of new products launched in the UK.

    Revenue mix by segment
    (Rs m) 1QFY03 1QFY04 % change
    Bulk drugs 1,753 1,655 -5.6%
    Branded Formulations 1,566 1,822 16.3%
    Generics 1,070 1,198 12.0%
    Others 144 137 -4.9%
    Total 4,533 4,812 6.2%

    Bulk Drugs:
    The bulk drugs segment was the only major segment of DRL that recorded negative growth. This was primarily on account of a 15% drop in revenues from the North American markets. Although there was a sharp decline in the revenues from 'Tizanidine', the drop was partially offset by growth in 'Naproxen sodium', 'Ranitidine Hcl form 1' and 'Sertraline'. The European and Indian markets also recorded a 32% and 8% decline respectively. DRL filed 3 US DMFs in the current quarter thereby taking the total filings to 43.

    Branded Formulations:
    Branded formulations segment was the top performer for the company. While the Indian markets registered a 15% growth, international markets saw an 18% increase.

    On the international front, growth was primarily fuelled by strong performance in Russia (contributing 68% of total international branded formulations revenues). In the Russian markets, the decline in revenues from ‘Enam’ was partially offset on account of growth recorded in 'Omez', 'Ciprolet' and 'Ketorol'.

    Coming to the domestic branded formulations market, strong performance in the key brands like 'Omez', 'Gaity', 'Stamlo', 'Stamlo Beta' and 'Enam' have helped DRL outperform the industry. Among the therapeutic segments, diabetic care, cardiovascular, and gastro intestinal segments were the top performers. The following table provides the therapeutic segment-wise breakup of the company’s revenues.

    Therapeutic distribution of domestic revenues (% of sales)
    Therapeutic segments 1QFY03 1QFY04
    Gastro intestinal 18 20
    Pain management 19 17
    Cardiovascular 16 18
    Anti infectives 12 10
    Naturals 13 11
    Others 22 24
    Total 100 100

    On the generics front, North America contributed 81% of the total revenues, with Europe making up for the rest. In the North American market, Fluoxetine capsules 40 mg accounted for Rs 588 m, while, Tizanidine tablets 2 & 4 mg contributed Rs 200 m. In the European market, new product launches including 'Omerprazole' were the key growth drivers. During 1QFY04, DRL made 1 Para 4 ANDA filing, taking the total number of ANDAs pending US FDA approval to 24.

    Others: In the other business segments that DRL operates, custom chemical services, diagnostics, critical care and biotechnology all recorded a decline. The decline in the diagnostic segment was due to the closure of diagnostic operations during the current quarter.

    During 1QFY04, DRL invested Rs 151 m in Aurigene Discovery Technologies and Aurigene Inc., bringing the total investments to Rs 852 m. The company also incurred capex of Rs 456 m.

    At the current price of Rs 1,037 DRL is currently trading at a P/E of 22.6x its consolidated 1QFY04 earnings. In view of the DRL’s increased focus on generics as well as new drug discovery research, US government’s thrust on promoting generics and the likely approval of Amlodipine Maleate, the future prospects of the company look positive. However, the risks inherent in drug discovery and the mounting legal expenses incurred while challenging existing patents remain. Hence, the investor must not base his decision on the outcome of a single court ruling.



    Equitymaster requests your view! Post a comment on "Dr. Reddy’s: Consolidation woes". Click here!


    More Views on News

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

    Sep 12, 2016

    Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 16, 2017 (Close)


    • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Compare Company With Charts